{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T11:42:42Z","timestamp":1771501362507,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.ejphar.2011.07.014","type":"journal-article","created":{"date-parts":[[2011,8,2]],"date-time":"2011-08-02T04:41:17Z","timestamp":1312260077000},"page":"84-93","source":"Crossref","is-referenced-by-count":41,"title":["Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models"],"prefix":"10.1016","volume":"669","author":[{"given":"Keiji","family":"Kusumoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Igata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mami","family":"Ojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuaki","family":"Imanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuminari","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanobu","family":"Kuroita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Nishigaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Nagaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2011.07.014_bb0005","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrcardio.2009.11","article-title":"Cardiovascular implications of proteinuria: an indicator of chronic kidney disease","volume":"6","author":"Agrawal","year":"2009","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0010","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0015","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2011.07.014_bb0020","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2165\/00003495-200262080-00016","article-title":"Candesartan cilexetil: an update of its use in essential hypertension","volume":"62","author":"Easthope","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2011.07.014_bb0025","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1161\/01.HYP.0000146909.69161.8c","article-title":"Management of hypertension in the very elderly patient","volume":"44","author":"Elliott","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2011.07.014_bb0030","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1185\/030079903125003017","article-title":"All antagonists in hypertension, heart failure, and diabetic nephropathy: focus on losartan","volume":"20","author":"Ferrario","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0035","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3317\/jraas.2000.044","article-title":"Lys(199) mutation of the human angiotensin type 1 receptor differentially affects the binding of surmountable and insurmountable non-peptide antagonists","volume":"1","author":"Fierens","year":"2000","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0040","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/01.hjh.0000170390.07321.ca","article-title":"Is interview a reliable method to verify the compliance with antihypertensive therapy? An international central-European study","volume":"23","author":"Fodor","year":"2005","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0045","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1677\/joe.0.1740321","article-title":"Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and \u03b2-oxidation in skeletal muscle","volume":"174","author":"Furuhashi","year":"2002","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0050","series-title":"Current Diagnosis & Treatment in Cardiology","first-page":"173","article-title":"Systemic hypertension","author":"Graettinger","year":"2003"},{"key":"10.1016\/j.ejphar.2011.07.014_bb0055","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1001\/jama.1990.03440210043030","article-title":"Cardiovascular risk factors in confirmed prediabetic individuals","volume":"263","author":"Haffner","year":"1990","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0060","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1161\/01.CIR.93.10.1809","article-title":"Insulin sensitivity and atherosclerosis","volume":"93","author":"Howard","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2011.07.014_bb0065","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0895-7061(94)00245-7","article-title":"Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives","volume":"8","author":"Iimura","year":"1995","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0070","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0022-3565(25)38647-7","volume":"268","author":"Inada","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0075","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.amjhyper.2006.12.010","article-title":"Azilsartan, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation","volume":"20","author":"Iwai","year":"2007","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0080","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/ki.2008.128","article-title":"Proteinuria in diabetic kidney disease: a mechanistic viewpoint","volume":"74","author":"Jefferson","year":"2008","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0085","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0895-7061(04)00899-4","article-title":"Blood pressure variability in hypertension: a possible cardiovascular risk factor","volume":"17","author":"Kario","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0090","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(05)70151-3","article-title":"Global burden of hypertension: analysis of worldwide data","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2011.07.014_bb0095","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/00005344-199424060-00010","article-title":"Antihypertensive and cardiovascular effects of a new potassium channel opener, TCV-295, in rats and dogs","volume":"24","author":"Kusumoto","year":"1994","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0100","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0105","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1161\/01.CIR.0000160923.04524.5B","article-title":"Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study","volume":"111","author":"Mancia","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2011.07.014_bb0110","doi-asserted-by":"crossref","first-page":"3J","DOI":"10.1016\/j.amjcard.2007.05.008","article-title":"Blood pressure reduction and cardiovascular outcomes: past, present, and future","volume":"100","author":"Mancia","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0115","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/01.HYP.0000215363.69793.bb","article-title":"Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure","volume":"47","author":"Mancia","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2011.07.014_bb0120","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1097\/HJH.0b013e3282f0580f","article-title":"2007 ESH-ESC practice guidelines for the management of arterial hypertension","volume":"25","author":"Mancia","year":"2007","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0125","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/01.fjc.0000245241.79959.d6","article-title":"The effect of angiotensin II receptor blockade on an end-stage renal failure model of type 2 diabetes","volume":"48","author":"Mizuno","year":"2006","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0130","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1291\/hypres.29.143","article-title":"Current status of antihypertensive prescription and associated blood pressure control in Japan","volume":"29","author":"Mori","year":"2006","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0135","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2165\/00003495-199141050-00006","article-title":"Sustained release nifedipine formulations","volume":"41","author":"Murdoch","year":"1991","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2011.07.014_bb0140","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0006-2952(93)90420-2","article-title":"Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist","volume":"46","author":"Noda","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0145","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1254\/jjp.85.416","article-title":"Involvement of angiotensin II in progression of renal injury in rats with genetic non-insulin-dependent diabetes mellitus (Wistar fatty rats)","volume":"85","author":"Noda","year":"2001","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/hr.2009.34","article-title":"The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)","volume":"32","author":"Ogihara","year":"2009","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0155","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(96)00837-0","article-title":"Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor","volume":"319","author":"Ojima","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0160","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/jpet.110.176636","article-title":"In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies","volume":"336","author":"Ojima","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0165","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0170","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/S0140-6736(00)04728-0","article-title":"Progression, remission, regression of chronic renal disease","volume":"357","author":"Ruggenenti","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2011.07.014_bb0175","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0022-3565(25)38306-0","volume":"266","author":"Shibouta","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"Suppl A","key":"10.1016\/j.ejphar.2011.07.014_bb0180","doi-asserted-by":"crossref","first-page":"A33","DOI":"10.1016\/S0149-2918(04)90144-0","article-title":"Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials","volume":"26","author":"Stumpe","year":"2004","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0185","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jama.287.8.1003","article-title":"Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study","volume":"287","author":"Vasan","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2011.07.014_bb0190","first-page":"183","article-title":"The angiotensin II receptor blockers: opportunities across the spectrum of cardiovascular disease","volume":"3","author":"Weber","year":"2002","journal-title":"Rev. Cardiovasc. Med."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0195","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/archinte.160.4.481","article-title":"Implications of a healthy lifestyle and medication analysis for improving hypertension control","volume":"160","author":"Weir","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ejphar.2011.07.014_bb0200","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/HYPERTENSIONAHA.110.163402","article-title":"Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension","volume":"57","author":"White","year":"2011","journal-title":"Hypertension"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299911007898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299911007898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T01:01:45Z","timestamp":1741395705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299911007898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":40,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0014299911007898"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2011.07.014","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}